Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas
Christian Lodberg
CL
Gastro-Immuno Research Laboratory, Department of Medicine V, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. chrishva@rm.dk
Kelsen
Jens
J
Agnholt
Jørgen
J
Dige
Anders
A
Christensen
Lisbet Ambrosius
LA
Dahlerup
Jens Frederik
JF
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000069285:Infliximab; D016023:Integrins / Q000378:metabolism; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D016023:Integrins; C071777:integrin alpha4beta7; D000069285:Infliximab